LU503014B1 - BRAIN-TONIFYING GRANULES AND PREPARATION METHOD THEREOF - Google Patents

BRAIN-TONIFYING GRANULES AND PREPARATION METHOD THEREOF Download PDF

Info

Publication number
LU503014B1
LU503014B1 LU503014A LU503014A LU503014B1 LU 503014 B1 LU503014 B1 LU 503014B1 LU 503014 A LU503014 A LU 503014A LU 503014 A LU503014 A LU 503014A LU 503014 B1 LU503014 B1 LU 503014B1
Authority
LU
Luxembourg
Prior art keywords
und
granules
von
tonifying
brain
Prior art date
Application number
LU503014A
Other languages
French (fr)
Inventor
Shuling Wang
Original Assignee
Univ Hangzhou Normal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Hangzhou Normal filed Critical Univ Hangzhou Normal
Application granted granted Critical
Publication of LU503014B1 publication Critical patent/LU503014B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969Polygonatum (Solomon's seal)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236Ligusticum (licorice-root)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482Cassia, e.g. golden shower tree
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/39Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50Methods involving additional extraction steps
    • A61K2236/51Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50Methods involving additional extraction steps
    • A61K2236/53Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are brain-tonifying granules and a preparation method thereof. The brain-tonifying granules are prepared from processed Rhizoma polygonati, processed Rhizoma polygonati odorati, Semen cassiae, Rhizoma chuanxiong and pharmaceutic auxiliary materials. The preparation process mainly includes: pretreatment of medicinal materials, extraction, filtration, concentration, alcohol precipitation, drying, granulation and the like. The brain-tonifying granules prepared by the preparation method of the present invention have the functions of nourishing the brain and calming the nerves, regulating five internal organs and harmonizing qi and blood, and also have the advantages of convenient use, convenient storage, convenient transportation and the like.Disclosed are brain-tonifying granules and a preparation method thereof. The brain-tonifying granules are prepared from processed Rhizoma polygonati, processed Rhizoma polygonati odorati, Semen cassiae, Rhizoma chuanxiong and pharmaceutical auxiliary materials. The preparation process mainly includes: pretreatment of medicinal materials, extraction, filtration, concentration, alcohol precipitation, drying, granulation and the like. The brain-tonifying granules prepared by the preparation method of the present invention have the functions of nourishing the brain and calming the nerves, regulating five internal organs and harmonizing qi and blood, and also have the advantages of convenient use, convenient storage, convenient transportation and the like.

Description

BL-5573BL-5573

BRAIN-TONIFYING GRANULES AND PREPARATION METHOD THEREOF | L/*0501$BRAIN-TONIFYING GRANULES AND PREPARATION METHOD THEREOF | L/*0501$

TECHNICAL FIELDTECHNICAL FIELD

[01] The present invention belongs to the technical field of preparation of drugs for external use, and particularly relates to brain-tonifying granules and a preparation method thereof.[01] The present invention belongs to the technical field of preparation of drugs for external use, and particularly relates to brain-tonifying granules and a preparation method thereof.

BACKGROUND ARTBACKGROUND ART

[02] With the development of China’s aging population, the incidence of insufficient brain power has been rising year by year, and the symptoms include insomnia, memory decline and the like. The disease has affected patients’ physical health and daily life, and has become an increasingly serious social problem.[02] With the development of China's aging population, the incidence of insufficient brain power has been rising year by year, and the symptoms include insomnia, memory decline and the like. The disease has affected patients' physical health and daily life, and has become an increasingly serious social problem.

[03] The experienced prescription of “Brain-tonifying Decoction” originated from[03] The experienced prescription of “Brain-tonifying Decoction” originated from

Wei Changchun, a prestigious doctor of traditional Chinese medicine, is composed of four medicinal materials: processed Rhizoma polygonati, processed Rhizoma polygonati odorati, Semen cassiae and Rhizoma chuanxiong. The prescription has the functions of nourishing the brain and calming the nerves, regulating five internal organs and harmonizing qi and blood, and has been widely applied in clinical practice. Following the idea of Monarch, Minister, Assistant and Guide in traditional Chinese medicine, the prescription takes Rhizoma polygonati and Rhizoma polygonati odorati as monarch, andWei Changchun, a prestigious doctor of traditional Chinese medicine, is composed of four medicinal materials: processed Rhizoma polygonati, processed Rhizoma polygonati odorati, Semen cassiae and Rhizoma chuanxiong. The prescription has the functions of nourishing the brain and calming the nerves, regulating five internal organs and harmonizing qi and blood, and has been widely applied in clinical practice. Following the idea of Monarch, Minister, Assistant and Guide in traditional Chinese medicine, the prescription takes Rhizoma polygonati and Rhizoma polygonati odorati as monarch, and

Semen cassiae and Rhizoma chuanxiong as minister. The main active components ofSemen cassiae and Rhizoma chuanxiong as minister. The main active components of

Rhizoma polygonati are polygahatous polysaccharides, saponins, flavonoids, etc. With extremely extensive pharmacological effects, the Rhizoma polygonati has the anti-aging, memory improvement, immunity enhancement and immunity functions. The Rhizoma polygonati odorati is sweet, mild in nature and slightly cold, has the functions of nourishing yin and moistening dryness, and engendering liquid and allaying thirst, and has the pharmacological effects of blood glucose lowering, immune regulation, anti-tumor, anti-oxidation, skin aging delaying, etc. The Rhizoma polygonati has the effect of regulating blood lipids. Moreover, the polygonatum polysaccharides and steroid saponins of the Rhizoma polygonati odorati are the main active components of playing pharmacological effects. The Rhizoma polygonati and Rhizoma polygonati odorati are used in the prescription, and the health function of such two medicines is similar. The modern pharmacological studies show that both of them have the functions of lowering blood glucose and regulating immunity. The Semen cassiae has the pharmacological effects of clearing liver and improving vision, regulating blood pressure and lowering blood lipids, relaxing bowel, etc. Studies show that the Semen cassiae not only has the main components of anthraquinones, but also has the volatile components and polysaccharide. The Rhizoma chuanxiong has the anti-inflammatory, anti-thrombosis, anti-asthma and other pharmacological effects, with the main components of volatile oil, alkaloid and polysaccharide.Rhizoma polygonati are polygahatous polysaccharides, saponins, flavonoids, etc. With extremely extensive pharmacological effects, the Rhizoma polygonati has the anti-aging, memory improvement, immunity enhancement and immunity functions. The Rhizoma polygonati odorati is sweet, mild in nature and slightly cold, has the functions of nourishing yin and moistening dryness, and engendering liquid and allaying thirst, and has the pharmacological effects of blood glucose lowering, immune regulation, anti-tumor, anti- oxidation, skin aging delay, etc. The Rhizoma polygonati has the effect of regulating blood lipids. Moreover, the polygonatum polysaccharides and steroid saponins of the Rhizoma polygonati odorati are the main active components of playing pharmacological effects. The Rhizoma polygonati and Rhizoma polygonati odorati are used in the prescription, and the health function of such two medicines is similar. The modern pharmacological studies show that both of them have the functions of lowering blood glucose and regulating immunity. The Semen cassiae has the pharmacological effects of clearing liver and improving vision, regulating blood pressure and lowering blood lipids, relaxing bowel, etc. Studies show that the Semen cassiae not only has the main components of anthraquinones, but also has the volatile components and polysaccharide. The Rhizoma chuanxiong has the anti-inflammatory, anti-thrombosis, anti-asthma and other pharmacological effects, with the main components of volatile oil, alkaloid and polysaccharide.

[04] The original prescription is the decoction prepared by the method that the medicinal materials are decocted or immersed in water, and the residue is discarded.[04] The original prescription is the decoction prepared by the method that the medicinal materials are decocted or immersed in water, and the residue is discarded.

The advantage of decoction lies in flexible components, in which the medicines can be increased or decreased according to the patient’s needs. The decoction takes effect 1The advantage of decoction lies in flexible components, in which the medicines can be increased or decreased according to the patient's needs. The decoction takes effect 1

BL-5573 quickly and is easy to absorb after oral administration. However, the disadvantage lies LU503014 in long dectocting time, inconvenient preservation, inconvenient carrying and inflexible drinking. In order to allow traditional Chinese medicine preparations to satisfy more needs, granules are derived. The granules retain the characteristics of quick response and easy absorption of traditional decoction, and have the advantages of short preparation time without decoction, precise dose, easy carrying, uniform specifications, consistent standards and the like.BL-5573 quickly and is easy to absorb after oral administration. However, the disadvantage lies LU503014 in long dectocting time, inconvenient preservation, inconvenient carrying and inflexible drinking. In order to allow traditional Chinese medicine preparations to satisfy more needs, granules are derived. The granules retain the characteristics of quick response and easy absorption of traditional decoction, and have the advantages of short preparation time without decoction, precise dose, easy carrying, uniform specifications, consistent standards and the like.

[05] The prescription is specific to the elderly people with insufficient brain power.[05] The prescription is specific to the elderly people with insufficient brain power.

With the development of China’s aging population, the incidence of insufficient brain power has been rising year by year, and the disease has become a hot social problem.With the development of China's aging population, the incidence of insufficient brain power has been rising year by year, and the disease has become a hot social problem.

The prescription has a wide audience range and a huge market demand as the elderly people with insufficient brain power are increasing. Moreover, the raw materials of the prescription are readily available and the preparation process is simple. The granules of the present invention can meet the needs of patients to the maximum extent while ensuring that the insufficient brain power can be effectively improved; moreover, the granules fill the market vacancy, so that economic benefits are considerable.The prescription has a wide audience range and a huge market demand as the elderly people with insufficient brain power are increasing. Moreover, the raw materials of the prescription are readily available and the preparation process is simple. The granules of the present invention can meet the needs of patients to the maximum extent while ensuring that the insufficient brain power can be effectively improved; moreover, the granules fill the market vacancy, so that economic benefits are considerable.

SUMMARYSUMMARY

[06] To solve the problems in the prior art, one objective of the present invention is to provide brain-tonifying granules.[06] To solve the problems in the prior art, one objective of the present invention is to provide brain-tonifying granules.

[07] The present invention is realized by the following technical solutions:[07] The present invention is realized by the following technical solutions:

[08] Brain-tonifying granules include an aqueous extract of plants and pharmaceutic auxiliary materials, wherein the aqueous extract of plants includes the following parts by weight of components: 25-35 parts of processed Rhizoma polygonati, 25-30 parts of processed Rhizoma polygonati odorati, 5-15 parts of Semen cassiae and 1-5 parts of[08] Brain-tonifying granules include an aqueous extract of plants and pharmaceutical auxiliary materials, wherein the aqueous extract of plants includes the following parts by weight of components: 25-35 parts of processed Rhizoma polygonati, 25-30 parts of processed Rhizoma polygonati odorati, 5-15 parts of Semen cassiae and 1-5 parts of

Rhizoma chuanxiong, the pharmaceutic auxiliary materials include a filling agent, a wetting agent and a binding agent, wherein the filling agent is one or more of sucrose, starch, dextrin, lactose, mannitol and sodium alginate; the filling agent is 30 wt%-60 wt%, and the binding agent is 0 wt%-5 wt%.Rhizoma chuanxiong, the pharmaceutical auxiliary materials include a filling agent, a wetting agent and a binding agent, wherein the filling agent is one or more of sucrose, starch, dextrin, lactose, mannitol and sodium alginate; the filling agent is 30 wt%-60 wt%, and the binding agent is 0 wt%-5 wt%.

[09] Preferably, the aqueous extract of plants includes the following parts by weight of components: 30 parts of processed Rhizoma polygonati, 30 parts of processed[09] Furthermore, the aqueous extract of plants includes the following parts by weight of components: 30 parts of processed Rhizoma polygonati, 30 parts of processed

Rhizoma polygonati odorati, 9 parts of Semen cassiae and 3 parts of Rhizoma chuanxiong.Rhizoma polygonati odorati, 9 parts of Semen cassiae and 3 parts of Rhizoma chuanxiong.

[10] Preferably, the wetting agent is 1 wt%-10 wt%; the wetting agent is 80%-95% ethanol (volume content) or water.[10] However, the wetting agent is 1 wt%-10 wt%; the wetting agent is 80%-95% ethanol (volume content) or water.

[11] Preferably, the binding agent is one of povidone, polyethylene glycol and hydroxy propyl cellulose.[11] However, the binding agent is one of povidone, polyethylene glycol and hydroxy propyl cellulose.

[12] Another objective of the present invention is to provide a method for preparing brain-tonifying granules, including the following steps:[12] Another objective of the present invention is to provide a method for preparing brain-tonifying granules, including the following steps:

[13] 1) weighing processed Rhizoma polygonati, processed Rhizoma polygonati odorati, Semen cassiae and Rhizoma chuanxiong respectively according to formula ratios, and mixing and crushing such raw materials to obtain a medicinal material mixture;[13] 1) weighing processed Rhizoma polygonati, processed Rhizoma polygonati odorati, Semen cassiae and Rhizoma chuanxiong respectively according to formula ratios, and mixing and crushing such raw materials to obtain a medicinal material mixture;

[14] 2) immersing the medicinal material mixture prepared in step 1) into a 6-fold to 2[14] 2) immersing the medicinal material mixture prepared in step 1) into a 6-fold to 2

BL-5573 10-fold amount (based on a mass of the medicinal material mixture) of purified water LU503014 for 1h, successively boiling with fast fire and decocting with slow fire the medicinal material mixture for 1h, and filtrating the medicinal material mixture; adding a 6-fold to 10-fold amount of purified water and boiling with fast fire and decocting with slow fire the medicinal material mixture for 1h again, combining the filtrate, and concentrating the combined filtrate to 1/3-2/3 of the original amount to obtain an aqueous extract concentrate;BL-5573 10-fold amount (based on a mass of the medicinal material mixture) of purified water LU503014 for 1h, successively boiling with fast fire and decocting with slow fire the medicinal material mixture for 1h, and filtrating the medicinal material mixture; adding a 6-fold to 10-fold amount of purified water and boiling with fast fire and decocting with slow fire the medicinal material mixture for 1h again, combining the filtrate, and concentrating the combined filtrate to 1/3-2/3 of the original amount to obtain an aqueous extract concentrate;

[15] 3) adding ethanol to the aqueous extract concentrate until the ethanol concentration reaches 60-80%(v/v), and placing the mixed solution in a refrigerator at 4°C for 24 h; mixing evenly and centrifugating the mixed solution, taking the supernatant and concentrating to 1/3-2/3 of the original amount, drying the concentrate under reduced pressure and crushing the dried productto obtain dry paste powder;[15] 3) adding ethanol to the aqueous extract concentrate until the ethanol concentration reaches 60-80%(v/v), and placing the mixed solution in a refrigerator at 4°C for 24 h; mixing evenly and centrifugating the mixed solution, taking the supernatant and concentrating to 1/3-2/3 of the original amount, drying the concentrate under reduced pressure and crushing the dried product to obtain dry paste powder;

[16] 4) turning on a high-speed stirring granulator, setting parameters, adding the dry paste powder and a filling agent to a mixing tank, and turning on an agitator blade for dry mixing; adding a binding agent and a wetting agent evenly in a wet mixing process, and turning on a cutter knife; upon completion of granulation, discharging granules and drying the granules at 60°C for 10-40 min; and[16] 4) turning on a high-speed stirring granulator, setting parameters, adding the dry paste powder and a filling agent to a mixing tank, and turning on an agitator blade for dry mixing; adding a binding agent and a wetting agent evenly in a wet mixing process, and turning on a cutter knife; upon completion of granulation, discharging granules and drying the granules at 60°C for 10-40 min; and

[17] 5) packaging the granules.[17] 5) packaging the granules.

[18] Preferably, the parameters of the high-speed stirring granulator are as follows: a dry mixing time is 3-5 min, a wet mixing time is 1-10 min, a granulation time is 1-4 min, a dry mixing stirring speed is 400-600 rpm, a wet mixing stirring speed is 400-600 rpm, a granulation stirring speed is 1,000-1,500 rpm, and a cutting speed is 2,000-3,000 rpm.[18] However, the parameters of the high-speed stirring granulator are as follows: a dry mixing time is 3-5 min, a wet mixing time is 1-10 min, a granulation time is 1-4 min, a dry mixing stirring speed is 400-600 rpm, a wet mixing stirring speed is 400-600 rpm, a granulation stirring speed is 1,000-1,500 rpm, and a cutting speed is 2,000-3,000 rpm.

[19] The present invention has the following advantages:[19] The present invention has the following advantages:

[20] The brain-tonifying granules of the present invention are prepared from processed Rhizoma polygonati, processed Rhizoma polygonati odorati, Semen cassiae,[20] The brain-tonifying granules of the present invention are prepared from processed Rhizoma polygonati, processed Rhizoma polygonati odorati, Semen cassiae,

Rhizoma chuanxiong and pharmaceutic auxiliary materials, and the preparation process mainly includes: pretreatment of medicinal materials, extraction, filtration, concentration, alcohol precipitation, drying, granulation and the like. The brain-tonifying granules prepared by the preparation method of the present invention have the functions of nourishing the brain and calming the nerves, regulating five internal organs and harmonizing qi and blood, and also have the advantages of convenient use, convenient storage, convenient transportation and the like.Rhizoma chuanxiong and pharmaceutical auxiliary materials, and the preparation process mainly includes: pretreatment of medicinal materials, extraction, filtration, concentration, alcohol precipitation, drying, granulation and the like. The brain-tonifying granules prepared by the preparation method of the present invention have the functions of nourishing the brain and calming the nerves, regulating five internal organs and harmonizing qi and blood, and also have the advantages of convenient use, convenient storage, convenient transportation and the like.

[21] The brain-tonifying granules have been proved safe and effective by quality inspection and pharmacodynamic experiment. On the basis of full consideration of practicality and effectiveness and previous research, the brain-tonifying granules not only retain the functions of the original prescription, such as nourishing the brain and calming the nerves, regulating five internal organs and harmonizing qi and blood, but also improve the disadvantages of inconvenient use and the like of the original decoction. Therefore, the brain-tonifying granules can not only adapt to market demand, but also have considerable economic benefits.[21] The brain-tonifying granules have been proven safe and effective by quality inspection and pharmacodynamic experiment. On the basis of full consideration of practicality and effectiveness and previous research, the brain-tonifying granules not only retain the functions of the original prescription, such as nourishing the brain and calming the nerves, regulating five internal organs and harmonizing qi and blood, but also improve the disadvantages of inconvenient use and the like of the original decoction. Therefore, the brain-tonifying granules can not only adapt to market demand, but also have considerable economic benefits.

BRIEF DESCRIPTION OF THE DRAWINGSBRIEF DESCRIPTION OF THE DRAWINGS

[22] FIG 1: Finished brain-tonifying granules.[22] FIG 1: Finished brain-tonifying granules.

[23] FIG 2: Schematic diagram of water maze. 3[23] FIG 2: Schematic diagram of water maze. 3

BL-5573BL-5573

[24] FIG 3: Experimental result diagram of water maze. LU503014[24] FIG 3: Experimental result diagram of water maze. LU503014

DETAILED DESCRIPTION OF THE EMBODIMENTSDETAILED DESCRIPTION OF THE EMBODIMENTS

[25] As previously mentioned, in view of the deficiencies in the prior art, the inventor put forward the technical solutions of the present invention through long-term research and extensive practice, mainly based on at least of the followings: 1) The brain-tonifying granules of the present invention include processed Rhizoma polygonati, processed Rhizoma polygonati odorati, Semen cassiae, Rhizoma chuanxiong and pharmaceutic auxiliary materials, and the preparation process mainly includes: pretreatment of medicinal materials, extraction, filtration, concentration, alcohol precipitation, drying, granulation and other processes. The brain-tonifying granules not only retain the functions of the original prescription, such as nourishing the brain and calming the nerves, regulating five internal organs and harmonizing qi and blood, but also improve the disadvantages of inconvenient use and the like of the original decoction. Therefore, the brain-tonifying granules can not only adapt to market demand, but also have considerable economic benefits. 2) The method of the present invention combines the two processes of mixing and granulation together by using a high-speed stirring granulator, which not only saves time but also meets the GMP requirements, reduces cross contamination and greatly improves the efficiency.[25] As previously mentioned, in view of the deficiencies in the prior art, the inventor put forward the technical solutions of the present invention through long-term research and extensive practice, mainly based on at least of the followings: 1) The brain -tonifying granules of the present invention include processed Rhizoma polygonati, processed Rhizoma polygonati odorati, Semen cassiae, Rhizoma chuanxiong and pharmaceutical auxiliary materials, and the preparation process mainly includes: pretreatment of medicinal materials, extraction, filtration, concentration, alcohol precipitation, drying, granulation and other processes. The brain-tonifying granules not only retain the functions of the original prescription, such as nourishing the brain and calming the nerves, regulating five internal organs and harmonizing qi and blood, but also improve the disadvantages of inconvenient use and the like of the original decoction . Therefore, the brain-tonifying granules can not only adapt to market demand, but also have considerable economic benefits. 2) The method of the present invention combines the two processes of mixing and granulation together by using a high-speed stirring granulator, which not only saves time but also meets the GMP requirements, reduces cross contamination and greatly improves the efficiency.

[26] To make the objectives, technical solutions, and advantages of the present invention clearer, the present invention will be further described below in detail in combination with the accompanying drawings and embodiments. It should be understood that specific embodiments described herein are only to explain the present invention but not to limit the present invention. In addition, the technical characteristics in the embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.[26] To make the objectives, technical solutions, and advantages of the present invention clearer, the present invention will be further described below in detail in combination with the accompanying drawings and embodiments. It should be understood that specific embodiments described herein are only to explain the present invention but not to limit the present invention. In addition, the technical characteristics in the embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.

[27] In the first aspect, a method for preparing brain-tonifying granules includes the following steps:[27] In the first aspect, a method for preparing brain-tonifying granules includes the following steps:

[28] 1) weighing 25-35 parts of processed Rhizoma polygonati, 25-30 parts of processed Rhizoma polygonati odorati, 5-15 parts of Semen cassiae and 1-5 parts of[28] 1) weighing 25-35 parts of processed Rhizoma polygonati, 25-30 parts of processed Rhizoma polygonati odorati, 5-15 parts of Semen cassiae and 1-5 parts of

Rhizoma chuanxiong, and mixing and crushing such raw materials to obtain a medicinal material mixture;Rhizoma chuanxiong, and mixing and crushing such raw materials to obtain a medicinal material mixture;

[29] 2) immersing the medicinal material mixture prepared in step 1) into a 6-fold to 10-fold amount (based on a mass of the medicinal material mixture) of purified water for 1h, successively boiling with fast fire and decocting with slow fire the medicinal material mixture for 1h, and filtrating the medicinal material mixture; adding a 6-fold to 10-fold amount of purified water and boiling with fast fire and decocting with slow fire the medicinal material mixture for 1h again, combining the filtrate, and concentrating the combined filtrate to 1/3-2/3 of the original amount to obtain an aqueous extract concentrate;[29] 2) immersing the medicinal material mixture prepared in step 1) into a 6-fold to 10-fold amount (based on a mass of the medicinal material mixture) of purified water for 1h, successively boiling with fast fire and decocting with slow fire the medicinal material mixture for 1h, and filtrating the medicinal material mixture; adding a 6-fold to 10-fold amount of purified water and boiling with fast fire and decocting with slow fire the medicinal material mixture for 1h again, combining the filtrate, and concentrating the combined filtrate to 1/3-2/3 of the original amount to obtain an aqueous extract concentrate;

[30] 3) adding ethanol to the aqueous extract concentrate until the ethanol concentration reaches 60-80%, and placing the mixed solution in a refrigerator at 4°C for 24 h; mixing evenly and centrifugating the mixed solution, taking the supernatant and concentrating to 1/3-2/3 of the original amount, drying the concentrate under 4[30] 3) adding ethanol to the aqueous extract concentrate until the ethanol concentration reaches 60-80%, and placing the mixed solution in a refrigerator at 4°C for 24 h; mixing evenly and centrifugating the mixed solution, taking the supernatant and concentrating to 1/3-2/3 of the original amount, drying the concentrate under 4

BL-5573 reduced pressure and crushing the dried product to obtain dry paste powder; LU503014BL-5573 reduced pressure and crushing the dried product to obtain dry paste powder; LU503014

[31] 4) turning on a high-speed stirring granulator, setting parameters, adding the dry paste powder and a filling agent to a mixing tank, and turning on an agitator blade for dry mixing; adding a binding agent and a wetting agent evenly in a wet mixing process, and turning on a cutter knife; upon completion of granulation, discharging granules and drying the granules at 60°C for 10-40 min; wherein the filling agent is one or more of sucrose, starch, dextrin, lactose, mannitol and sodium alginate; the filling agent is 30[31] 4) turning on a high-speed stirring granulator, setting parameters, adding the dry paste powder and a filling agent to a mixing tank, and turning on an agitator blade for dry mixing; adding a binding agent and a wetting agent evenly in a wet mixing process, and turning on a cutter knife; upon completion of granulation, discharging granules and drying the granules at 60°C for 10-40 min; wherein the filling agent is one or more of sucrose, starch, dextrin, lactose, mannitol and sodium alginate; the filling agent is 30

Wt%-60 wt%, and the binding agent is 0 wt%-5 wt%; andWt%-60 wt%, and the binding agent is 0 wt%-5 wt%; and

[32] 5) packaging the granules.[32] 5) packaging the granules.

[33] Preferably, the wetting agent is 1 wt%-10 wt%;[33] However, the wetting agent is 1 wt%-10 wt%;

[34] preferably, the wetting agent is 80%-95% ethanol or water.[34] Preferably, the wetting agent is 80%-95% ethanol or water.

[35] Preferably, the binding agent is one of povidone, polyethylene glycol and hydroxy propyl cellulose.[35] However, the binding agent is one of povidone, polyethylene glycol and hydroxy propyl cellulose.

[36] Preferably, the parameters of the high-speed stirring granulator in step 4) are as follows: a dry mixing time is 3-5 min, a wet mixing time is 1-10 min, a granulation time is 1-4 min, a dry mixing stirring speed is 400-600 rpm, a wet mixing stirring speed is 400-600 rpm, a granulation stirring speed is 1,000-1,500 rpm, and a cutting speed is 2,000-3,000 rpm.[36] However, the parameters of the high-speed stirring granulator in step 4) are as follows: a dry mixing time is 3-5 min, a wet mixing time is 1-10 min, a granulation time is 1-4 min , a dry mixing stirring speed is 400-600 rpm, a wet mixing stirring speed is 400-600 rpm, a granulation stirring speed is 1,000-1,500 rpm, and a cutting speed is 2,000-3,000 rpm.

[37] In the second aspect, brain-tonifying granules include an aqueous extract of plants and pharmaceutic auxiliary materials; wherein the aqueous extract of plants includes the following parts by weight of components: 25-35 parts of processed[37] In the second aspect, brain-tonifying granules include an aqueous extract of plants and pharmaceutical auxiliary materials; wherein the aqueous extract of plants includes the following parts by weight of components: 25-35 parts of processed

Rhizoma polygonati, 25-30 parts of processed Rhizoma polygonati odorati, 5-15 parts ofRhizoma polygonati, 25-30 parts of processed Rhizoma polygonati odorati, 5-15 parts of

Semen cassiae and 1-5 parts of Rhizoma chuanxiong, the pharmaceutic auxiliary materials include a filling agent, a wetting agent and a binding agent.Semen cassiae and 1-5 parts of Rhizoma chuanxiong, the pharmaceutical auxiliary materials include a filling agent, a wetting agent and a binding agent.

[38] The technical solutions of the present invention will be further explained below in combination with some preferred embodiments, but the experimental conditions and set parameters therein should not be regarded as a limitation to the basic technical solutions of the present invention. Moreover, the protection scope of the present invention is not limited to the following embodiments.[38] The technical solutions of the present invention will be further explained below in combination with some preferred embodiments, but the experimental conditions and set parameters therein should not be regarded as a limitation to the basic technical solutions of the present invention. Moreover, the protection scope of the present invention is not limited to the following embodiments.

[39] Example 1[39] Example 1

[40] 30g of processed Rhizoma polygonati, 30g of processed Rhizoma polygonati odorati, 9g of Semen cassiae and 3g of Rhizoma chuanxiong were weighed respectively, and mixed and crushed to obtain a medicinal material mixture. A 10-fold amount (based on a mass of the medicinal material mixture) of purified water was added, and the medicinal material mixture was immersed for 1h, boiled with fast fire and decocted with slow fire for 1h, and filtrated. An 8-fold amount of purified water was added, the medicinal material mixture was immersed for 1h, boiled with fast fire and decocted with slow fire for 1h again. The filtrate was combined, and the combined filtrate was concentrated to 2/5 of the original amount to obtain an aqueous extract concentrate.[40] 30g of processed Rhizoma polygonati, 30g of processed Rhizoma polygonati odorati, 9g of Semen cassiae and 3g of Rhizoma chuanxiong were weighed respectively, and mixed and crushed to obtain a medicinal material mixture. A 10-fold amount (based on a mass of the medicinal material mixture) of purified water was added, and the medicinal material mixture was immersed for 1h, boiled with fast fire and decocted with slow fire for 1h, and filtrated. An 8-fold amount of purified water was added, the medicinal material mixture was immersed for 1h, boiled with fast fire and decocted with slow fire for 1h again. The filtrate was combined, and the combined filtrate was concentrated to 2/5 of the original amount to obtain an aqueous extract concentrate.

Ethanol was added to the aqueous extract concentrate until the ethanol concentration reached 75%, and the mixed solution was placed in a refrigerator at 4°C for 24h. The mixed solution was mixed evenly and centrifugated, the supernatant was taken and concentrated to 2/5 of the original amount. The resulting concentrate was dried under reduced pressure, and the dried product was crushed to obtain dry paste powder. A 5Ethanol was added to the aqueous extract concentrate until the ethanol concentration reached 75%, and the mixed solution was placed in a refrigerator at 4°C for 24h. The mixed solution was mixed evenly and centrifuged, the supernatant was taken and concentrated to 2/5 of the original amount. The resulting concentrate was dried under reduced pressure, and the dried product was crushed to obtain dry paste powder. AT 5

BL-5573 high-speed stirring granulator was turned on, and parameters were set (a dry mixing LU503014 time was 5 min, a wet mixing time was 3 min, a granulation time was 4 min, a dry mixing stirring speed was 400 rpm, a wet mixing stirring speed was 500 rpm, a granulation stirring speed was 1,200 rpm, and a cutting speed was 2,500 rpm). 2 kg of dry paste powder and 1 kg of filling agent (sodium alginate:mannitol = 3:1) were added to a mixing tank, and an agitator blade was turned on for dry mixing. 90 g of 95% ethanol was evenly added in a wet mixing process, and a cutter knife was turned on.BL-5573 high-speed stirring granulator was turned on, and parameters were set (a dry mixing LU503014 time was 5 min, a wet mixing time was 3 min, a granulation time was 4 min, a dry mixing stirring speed was 400 rpm, a wet mixing stirring speed was 500 rpm, a granulation stirring speed was 1,200 rpm, and a cutting speed was 2,500 rpm). 2 kg of dry paste powder and 1 kg of filling agent (sodium alginate:mannitol = 3:1) were added to a mixing tank, and an agitator blade was turned on for dry mixing. 90 g of 95% ethanol was evenly added in a wet mixing process, and a cutter knife was turned on.

Upon completion of granulation, granules were discharged and dried at 60°C for 20 min.Upon completion of granulation, granules were discharged and dried at 60°C for 20 min.

[41] According to the appearance and the inspection items of particle size, moisture and solubility of granules in Chinese Pharmacopoeia (2020 Edition), the indicators of the brain-tonifying granules prepared in example 1 were tested. The results are as shown in Table 1, and the finished product picture is as shown in FIG 1.[41] According to the appearance and the inspection items of particle size, moisture and solubility of granules in Chinese Pharmacopoeia (2020 Edition), the indicators of the brain-tonifying granules prepared in example 1 were tested. The results are as shown in Table 1, and the finished product picture is as shown in FIG 1.

[42] Table 1 Test Results[42] Table 1 Test Results

Test Item Test ResultTest Item Test Result

Color Brown -Color Brown -

Particle size (96.18+0.28)% QualifiedParticle size (96.18+0.28)% Qualified

Water content (6.02+0.28)% QualifiedWater content (6.02+0.28)% Qualified

Solubility Dissolved without Qualified precipitationSolubility Dissolved without Qualified precipitation

[43] Example 2[43] Example 2

[44] High-temperature test: The brain-tonifying granules prepared in example 1 and brain-tonifying decoction (an aqueous extract from 30 g of processed Rhizoma polygonati, 30 g of processed Rhizoma polygonati odorati, 9 g of Semen cassiae and 3 g of Rhizoma chuanxiong in example 1) were placed in a drug stability test chamber at (60+2)°C and constant humidity respectively, samples were taken on days 0, 5 and 10 respectively to inspect characters, and the contents of total polysaccharides and ligustrazine were tested on day 10. The results showed that at high temperature, the brain-tonifying granules had uniform color without agglomeration on days 0, 5 and 10, while a part of granular precipitation appeared in the brain-tonifying decoction from day 5, and a large amount of precipitation and corruption appeared on day 10. The contents of total polysaccharides and ligustrazine were tested on day 10 (calculated according to an initial concentration of each component being 100%), and a change amount of each component was calculated. A content of total polysaccharides in the brain-tonifying granules was 98.60% of the initial concentration, and a content of ligustrazine was 98.63% of the initial concentration; after day 10, a content of total polysaccharides in the brain-tonifying decoction was 76.24% of the initial concentration, and a content of ligustrazine was 85.78% of the initial concentration.[44] High-temperature test: The brain-tonifying granules prepared in example 1 and brain-tonifying decoction (an aqueous extract from 30 g of processed Rhizoma polygonati, 30 g of processed Rhizoma polygonati odorati, 9 g of Semen cassiae and 3 g of Rhizoma chuanxiong in example 1) were placed in a drug stability test chamber at (60+2)°C and constant humidity respectively, samples were taken on days 0, 5 and 10 respectively to inspect characters, and the contents of total polysaccharides and ligustrazine were tested on day 10. The results showed that at high temperature, the brain-tonifying granules had uniform color without agglomeration on days 0, 5 and 10, while a part of granular precipitation appeared in the brain-tonifying decoction from day 5, and a large amount of precipitation and corruption appeared on day 10. The contents of total polysaccharides and ligustrazine were tested on day 10 (calculated according to an initial concentration of each component being 100%), and a change amount of each component was calculated. A content of total polysaccharides in the brain-tonifying granules was 98.60% of the initial concentration, and a content of ligustrazine was 98.63% of the initial concentration; after day 10, a content of total polysaccharides in the brain-tonifying decoction was 76.24% of the initial concentration, and a content of ligustrazine was 85.78% of the initial concentration.

[45] Acceleration test: The brain-tonifying granules prepared in example 1 and brain-tonifying decoction were placed in a drug stability test chamber at (40+2)°C and a relative humidity of 75% respectively, samples were taken in months 0, 3 and 6 respectively to inspect characters, and the contents of total polysaccharides and ligustrazine were tested in month 6. The results showed that in the acceleration test, the brain-tonifying granules had uniform color without agglomeration in months 3 and 6, 6[45] Acceleration test: The brain-tonifying granules prepared in example 1 and brain-tonifying decoction were placed in a drug stability test chamber at (40+2)°C and a relative humidity of 75% respectively, samples were taken in months 0, 3 and 6 respectively to inspect characters, and the contents of total polysaccharides and ligustrazine were tested in month 6. The results showed that in the acceleration test, the brain-tonifying granules had uniform color without agglomeration in months 3 and 6, 6

BL-5573 while obvious precipitation appeared in the brain-tonifying decoction in month 3, and a LU503014 large amount of precipitation and corruption appeared in month 6. The contents of total polysaccharides and ligustrazine were tested in month 6 (calculated according to an initial concentration of each component being 100%). À content of total polysaccharides in the brain-tonifying granules was 96.65% of the initial concentration, and a content of ligustrazine was 98.17% of the initial concentration; a content of total polysaccharides in the brain-tonifying decoction was 65.36% of the initial concentration, and a content of ligustrazine was 81.23% of the initial concentration.BL-5573 while obvious precipitation appeared in the brain-tonifying decoction in month 3, and a LU503014 large amount of precipitation and corruption appeared in month 6. The contents of total polysaccharides and ligustrazine were tested in month 6 (calculated according to an initial concentration of each component being 100%). À content of total polysaccharides in the brain-tonifying granules was 96.65% of the initial concentration, and a content of ligustrazine was 98.17% of the initial concentration; a content of total polysaccharides in the brain-tonifying decoction was 65.36% of the initial concentration, and a content of ligustrazine was 81.23% of the initial concentration.

[46] To sum up, the brain-tonifying granules of the present invention have good stability and stable quality, and have obvious advantages over the brain-tonifying decoction.[46] To sum up, the brain-tonifying granules of the present invention have good stability and stable quality, and have obvious advantages over the brain-tonifying decoction.

[47] Example 3[47] Example 3

[48] Water maze experiment method: The schematic diagram of SMG-2 water maze is as shown in FIG 2. The program was opened, the file was left-clicked, and the “Start of Experiment” was selected. At this time, a recording window popped up, and the behaviors (times of entering the blind ends and latency) of the first mouse were recorded. When the mouse swam to the step, the recording automatically stopped and the time was locked. “Finish” was clicked, and the experimental results were listed in detail. When the second mouse was ready, the above procedure was repeated. During the experimental training, the passage between point A and point B was blocked with a partition on the first day of training, and one mouse placed on the step for 10 s so that the mouse was aware of the existence of the safe area; then the mouse was placed at the starting point A and allowed to swim freely, and the times (i.e., error times) that the mouse entered the blind end 1 and the time (i.e., latency) that the mouse climbed the safe step were recorded; the mouse that could not find the step within 2 min would be directed to the safe step, and the latency would be recorded as 2 min. After the first training, the mouse was allowed to have a rest and trained again according to the same method. Other mice were trained successively. On the second day of training, the partition was placed at the point B, and the starting point for swimming was point B; the error times that the mouse entered the blind ends 1, 2 and 3 within 2 min and the latency that the mouse climbed the safe step were recorded respectively, and each mouse was trained twice continuously. The mice that could not find the step within 2 min would be directed to the end point, and the latency would be recorded as 2 min. From the third day to the fifth day of training, the partition was removed, and the starting point for swimming was point C; the error times that the mice entered the blind ends 1, 2, 3 and 4 within 2 min and the latency that the mice found the safe step were recorded, and each mouse was trained twice continuously. Upon completion of training, the mice were allowed to rest for a day, and the test was performed on the seventh day. The starting point was still point C, and the time was 2 min. The times that the mice entered the blind ends 1, 2, 3, and 4 were recorded as the error times, and the time that the mice found the safe step was recorded as the latency.[48] Water maze experiment method: The schematic diagram of SMG-2 water maze is as shown in FIG 2. The program was opened, the file was left-clicked, and the “Start of Experiment” was selected. At this time, a recording window popped up, and the behaviors (times of entering the blind ends and latency) of the first mouse were recorded. When the mouse swam to the step, the recording automatically stopped and the time was locked. “Finish” was clicked, and the experimental results were listed in detail. When the second mouse was ready, the above procedure was repeated. During the experimental training, the passage between point A and point B was blocked with a partition on the first day of training, and one mouse placed on the step for 10 s so that the mouse was aware of the existence of the safe area; then the mouse was placed at the starting point A and allowed to swim freely, and the times (i.e., error times) that the mouse entered the blind end 1 and the time (i.e., latency) that the mouse climbed the safe step were recorded ; the mouse that could not find the step within 2 min would be directed to the safe step, and the latency would be recorded as 2 min. After the first training, the mouse was allowed to have a rest and trained again according to the same method. Other mice were trained successively. On the second day of training, the score was placed at the point B, and the starting point for swimming was point B; the error times that the mouse entered the blind ends 1, 2 and 3 within 2 min and the latency that the mouse climbed the safe step were recorded respectively, and each mouse was trained twice continuously. The mice that could not find the step within 2 min would be directed to the end point, and the latency would be recorded as 2 min. From the third day to the fifth day of training, the partition was removed, and the starting point for swimming was point C; the error times that the mice entered the blind ends 1, 2, 3 and 4 within 2 min and the latency that the mice found the safe step were recorded, and each mouse was trained twice continuously. Upon completion of training, the mice were allowed to rest for a day, and the test was performed on the seventh day. The starting point was still point C, and the time was 2 min. The times that the mice entered the blind ends 1, 2, 3, and 4 were recorded as the error times, and the time that the mice found the safe step was recorded as the latency.

[49] 12 ICR mice were randomly divided into 4 groups for administration dose pre-experiment of scopolamine. A water maze experiment was used, and the experimental data were recorded and analyzed to obtain an optimal dose for modeling. 7[49] 12 ICR mice were randomly divided into 4 groups for administration dose pre-experiment of scopolamine. A water maze experiment was used, and the experimental data were recorded and analyzed to obtain an optimal dose for modeling. 7

BL-5573BL-5573

The determined experimental results of scopolamine dose for modeling are as shown in LU503014The determined experimental results of scopolamine dose for modeling are as shown in LU503014

Table 2. With the increase of scopolamine dose, the latency of the mice in the water maze also increased gradually, demonstrating that the scopolamine could decrease the learning and memory ability of the mice, and the model was successfully built. However, through data analysis, independent-samples T-test was performed on the data of the low-dose group, the middle-dose group and the blank control group, P > 0.05, showing no significant difference; the independent-samples T-test was performed on the data of the high-dose group and the blank control group, and P was 0.02, less than 0.05.Table 2. With the increase of scopolamine dose, the latency of the mice in the water maze also increased gradually, demonstrating that the scopolamine could decrease the learning and memory ability of the mice, and the model was successfully built. However, through data analysis, independent-samples T-test was performed on the data of the low-dose group, the middle-dose group and the blank control group, P > 0.05, showing no significant difference; the independent-samples T-test was performed on the data of the high-dose group and the blank control group, and P was 0.02, less than 0.05.

Therefore, the high-dose group showed a significant difference, so 3 mg/kg scopolamine was selected as the dose for modeling in the following experiment.Therefore, the high-dose group showed a significant difference, so 3 mg/kg scopolamine was selected as the dose for modeling in the following experiment.

[50] Table 2 Modeling Groups of Scopolamine and Administration Doses[50] Table 2 Modeling Groups of Scopolamine and Administration Doses

Group Administration LatencyGroup Administration Latency

Low-dose group Scopolamine (1 mg/kg) 7.24+4.00Low-dose group Scopolamine (1 mg/kg) 7.24+4.00

Middle-dose group Scopolamine (2 mg/kg) 93.56+3.19Middle-dose group Scopolamine (2 mg/kg) 93.56+3.19

High-dose group Scopolamine (3 mg/kg) 100.97+16.54High-dose group Scopolamine (3 mg/kg) 100.97+16.54

Blank control group Normal saline 60.45+7.41Blank control group Normal saline 60.45+7.41

[51] 12 ICR mice were randomly divided into 4 groups for administration dose pre-experiment of brain-tonifying granules. A water maze experiment was used, and the experimental data were recorded and analyzed to obtain an approximate dose range of the brain-tonifying granules. The administration dose used was converted from the administration dose of the brain-tonifying decoction, and the administration dose of mice was calculated by the following pharmacokinetic formula: (ONE[51] 12 ICR mice were randomly divided into 4 groups for administration dose pre-experiment of brain-tonifying granules. A water maze experiment was used, and the experimental data were recorded and analyzed to obtain an approximate dose range of the brain-tonifying granules. The administration dose used was converted from the administration dose of the brain-tonifying decoction, and the administration dose of mice was calculated by the following pharmacokinetic formula: (ONE

[52][52]

[53] where Kmice = 9.1, Khuman = 10.6. The body weight of mice is calculated as 20 g, and the body weight of humans is calculated as 60 kg, so a ratio of the body surface area of adults to the body surface area of mice is 242.47:1.[53] where Kmice = 9.1, Khuman = 10.6. The body weight of mice is calculated as 20 g, and the body weight of humans is calculated as 60 kg, so a ratio of the body surface area of adults to the body surface area of mice is 242.47:1.

[54] As shown in Table 3, the latency in the negative control group was the longest, while the latency in the administration groups was significantly less than that in the negative control group. However, the independent-samples T-test was performed on the data of the low-dose group, the middle-dose group and the negative control group by[54] As shown in Table 3, the latency in the negative control group was the longest, while the latency in the administration groups was significantly less than that in the negative control group. However, the independent-samples T-test was performed on the data of the low-dose group, the middle-dose group and the negative control group by

IBM SPSS Statistics 23, P > 0.05, showing no significant difference; P of the T-test between the high-dose group and the negative control group was less than 0.05, showing a significant difference. Therefore, the administration dose of the brain-tonifying granules should be 8 g/kg in the following experiment.IBM SPSS Statistics 23, P > 0.05, showing no significant difference; P of the T-test between the high-dose group and the negative control group was less than 0.05, showing a significant difference. Therefore, the administration dose of the brain-tonifying granules should be 8 g/kg in the following experiment.

[55] Table 3 Pre-experiment Groups of Brain-tonifying Granules and Administration[55] Table 3 Pre-experiment Groups of Brain-tonifying Granules and Administration

DosesRates

Group Drug Administration Latency (n=3)Group Drug Administration Latency (n=3)

Low-dose group Brain-tonifying granules 67.68+5.42 (2 g/kg)Low-dose group Brain-tonifying granules 67.68+5.42 (2 g/kg)

Middle-dose group Brain-tonifying granules 84.50+10.45 (4 g/kg) 8Middle-dose group Brain-tonifying granules 84.50+10.45 (4 g/kg) 8

BL-5573BL-5573

High-dose group Brain-tonifying granules 53.19+6.44 LUS03014 (8 g/kg)High-dose group Brain-tonifying granules 53.19+6.44 LUS03014 (8 g/kg)

Blank control group Drinking water 99.25+16.25Blank control group Drinking water 99.25+16.25

[56] 60 mice were divided into 6 groups, 10 mice in each group, which were a blank control group, a negative control group, a high-dose group, a middle-dose group and a low-dose group respectively. In the aspect of modeling, the blank control group was injected intraperitoneally with normal saline, while the other groups were injected intraperitoneally with scopolamine at a dose of 3 mg/kg. In the aspect of administration, the blank control group and the negative control group were given drinking water, the high-dose, middle-dose and low-dose groups were given brain-tonifying granules, and the positive control group was given a brain-tonifying oral solution (the brain-tonifying oral solution was prepared according to the method in CN107308323A, wherein a mass ratio of processed Rhizoma polygonati to processed Rhizoma polygonati odorati to[56] 60 mice were divided into 6 groups, 10 mice in each group, which were a blank control group, a negative control group, a high-dose group, a middle-dose group and a low-dose group respectively. In the aspect of modeling, the blank control group was injected intraperitoneally with normal saline, while the other groups were injected intraperitoneally with scopolamine at a dose of 3 mg/kg. In the aspect of administration, the blank control group and the negative control group were given drinking water, the high-dose, middle-dose and low-dose groups were given brain-tonifying granules, and the positive control group was given a brain- tonifying oral solution (the brain-tonifying oral solution was prepared according to the method in CN107308323A, wherein a mass ratio of processed Rhizoma polygonati to processed Rhizoma polygonati odorati to

Semen cassiae to Rhizoma chuanxiong was 30:30:9:3), as shown in Table 4.Semen cassiae to Rhizoma chuanxiong was 30:30:9:3), as shown in Table 4.

[57] Table 4 Functional Experimental Groups of Brain-tonifying Granules (n=10)[57] Table 4 Functional Experimental Groups of Brain-tonifying Granules (n=10)

Group Drug for Modeling AdministrationGroup Drug for Modeling Administration

Blank control group Normal saline Drinking waterBlank control group Normal saline Drinking water

Negative control group Scopolamine (3 mg/kg) Drinking waterNegative control group Scopolamine (3 mg/kg) Drinking water

High-dose group Scopolamine (3 mg/kg) Brain-tonifying granules (16 g/kg/d)High-dose group Scopolamine (3 mg/kg) Brain-tonifying granules (16 g/kg/d)

Middle-dose group Scopolamine (3 mg/kg) Brain-tonifying granules (8 g/kg/d)Middle-dose group Scopolamine (3 mg/kg) Brain-tonifying granules (8 g/kg/d)

Low-dose group Scopolamine (3 mg/kg) Brain-tonifying granules (4 g/kg/d)Low-dose group Scopolamine (3 mg/kg) Brain-tonifying granules (4 g/kg/d)

Brain-tonifying oral Scopolamine (3 mg/kg) Brain-tonifying oral solution (6 solution group ml/kg/d)Brain-tonifying oral Scopolamine (3 mg/kg) Brain-tonifying oral solution (6 solution group ml/kg/d)

[58] The water maze experimental results are as shown in Table 5 and FIG 3. As shown in the figure, the latency of the blank control group in the water maze was the shortest, while the latency of the negative control group was the longest. The independent-samples T-test was performed on the data of the two groups, and P was 0.01, indicating that the model was successfully built. For the latency of mice in the low-dose group, the brain-tonifying granules had a certain improvement effect on the learning and memory ability of the mice, but the independent-samples T-test showed no significant difference with the negative control group. The independent-samples T-test was performed on the data of the middle-dose group, the high-dose group and the negative control group, and P was 0.040 and 0.040 respectively, showing a significant difference. Therefore, the water maze experiment showed that the brain-tonifying granules were positive in improving the learning and memory ability. For the brain-tonifying oral solution group, the latency was shorter than that of the brain-tonifying granules group, but no significant difference was shown.[58] The water maze experimental results are as shown in Table 5 and FIG 3. As shown in the figure, the latency of the blank control group in the water maze was the shortest, while the latency of the negative control group was the longest . The independent-samples T-test was performed on the data of the two groups, and P was 0.01, indicating that the model was successfully built. For the latency of mice in the low-dose group, the brain-tonifying granules had a certain improvement effect on the learning and memory ability of the mice, but the independent-samples T-test showed no significant difference with the negative control group. The independent-samples T-test was performed on the data of the middle-dose group, the high-dose group and the negative control group, and P was 0.040 and 0.040 respectively, showing a significant difference. Therefore, the water maze experiment showed that the brain-tonifying granules were positive in improving the learning and memory ability. For the brain-tonifying oral solution group, the latency was shorter than that of the brain-tonifying granules group, but no significant difference was shown.

[59] Table 5 Water Maze Experiment of Brain-tonifying Granules[59] Table 5 Water Maze Experiment of Brain-tonifying Granules

Mouse Blank Negative Low-dose Middle-dose High-dose NegativeMouse Blank Negative Low-dose Middle-dose High-dose Negative

No. Control Control Group Group Group ControlNo. Control Control Group Group Group Control

Group Group Group 1 46.23 120 86.54 72.91 82.21 42.61 2 59.42 96.48 75.31 58.37 48.46 66.94 9Group Group Group 1 46.23 120 86.54 72.91 82.21 42.61 2 59.42 96.48 75.31 58.37 48.46 66.94 9

BL-5573 3 32.33 38.64 63.21 72.35 120 4937 14509014 4 31.49 93.86 64.52 71.29 49.65 74.29 29.87 104.67 59.82 73.68 55.26 43.61 6 60.54 112.32 120 66.91 120 85.87 7 120 107.29 109.87 110.74 49.13 67.14 8 38.24 92.81 100.45 70.11 38.16 69.87 9 49.51 120 120 68.07 111.27 69.54 61.68 120 62.76 65.81 43.29 40.09BL-5573 3 32.33 38.64 63.21 72.35 120 4937 14509014 4 31.49 93.86 64.52 71.29 49.65 74.29 29.87 104.67 59.82 73.68 55.26 4 3.61 6 60.54 112.32 120 66.91 120 85.87 7 120 107.29 109.87 110.74 49.13 67.14 8 38.24 92.81 100.45 70.11 38.16 69.87 9 49. 51 120 120 68.07 111.27 69.54 61.68 120 62.76 65.81 43.29 40.09

[60] Finally, it should be stated that the foregoing are only the preferred embodiments of the present invention, but are not intended to limit the present invention.[60] Finally, it should be stated that the foregoing are only the preferred embodiments of the present invention, but are not intended to limit the present invention.

Although the present invention is described in detail by reference to the above-mentioned embodiments, modifications to the technical solutions recorded in the 5 above-mentioned embodiments, or equivalent substitutions to a part of technical characteristics thereof may be made by those skilled in the art still. Any modifications, equivalent substitutions or improvements made within the spirit and principles of the present invention should be regarded to fall into the protection scope of the present invention. 10Although the present invention is described in detail by reference to the above-mentioned embodiments, modifications to the technical solutions recorded in the 5 above-mentioned embodiments, or equivalent substitutions to a part of technical characteristics thereof may be made by those skilled in the art still. Any modifications, equivalent substitutions or improvements made within the spirit and principles of the present invention should be regarded to fall into the protection scope of the present invention. 10

Claims (8)

BL-5573 CLAIMS LU503014BL-5573 CLAIMS LU503014 1. A method for preparing brain-tonifying granules, comprising the following steps: 1) weighing 25-35 parts of processed Rhizoma polygonati, 25-30 parts of processed Rhizoma polygonati odorati, 5-15 parts of Semen cassiae and 1-5 parts of Rhizoma chuanxiong, and mixing and crushing such raw materials to obtain a medicinal material mixture; 2) immersing the medicinal material mixture prepared in step 1) into a 6-fold to 10-fold amount (based on a mass of the medicinal material mixture) of purified water for 1h, successively boiling with fast fire and decocting with slow fire the medicinal material mixture for 1h, and filtrating the medicinal material mixture; adding a 6-fold to 10-fold amount of purified water and boiling with fast fire and decocting with slow fire the medicinal material mixture for 1h again, combining the filtrate, and concentrating the combined filtrate to 1/3-2/3 of the original amount to obtain an aqueous extract concentrate; 3) adding ethanol to the aqueous extract concentrate until the ethanol concentration reaches 60-80%, and placing the mixed solution in a refrigerator at 4°C for 24 h; mixing evenly and centrifugating the mixed solution, taking the supernatant and concentrating to 1/3-2/3 of the original amount, drying the concentrate under reduced pressure and crushing the dried product to obtain dry paste powder; 4) turning on a high-speed stirring granulator, setting parameters, adding the dry paste powder and a filling agent to a mixing tank, and turning on an agitator blade for dry mixing; adding a binding agent and a wetting agent evenly in a wet mixing process, and turning on a cutter knife; upon completion of granulation, discharging the granules and drying the granules at 60°C for 10-40 min; wherein the filling agent is one or more of sucrose, starch, dextrin, lactose, mannitol and sodium alginate; the filling agent is 30 wt%-60 wt%, and the binding agent is 0 wt%-5 wt%; and 5) packaging the granules.1. A method for preparing brain-tonifying granules, comprising the following steps: 1) weighing 25-35 parts of processed Rhizoma polygonati, 25-30 parts of processed Rhizoma polygonati odorati, 5-15 parts of Semen cassiae and 1-5 parts of Rhizoma chuanxiong, and mixing and crushing such raw materials to obtain a medicinal material mixture; 2) immersing the medicinal material mixture prepared in step 1) into a 6-fold to 10-fold amount (based on a mass of the medicinal material mixture) of purified water for 1h, successively boiling with fast fire and decocting with slow fire the medicinal material mixture for 1h, and filtrating the medicinal material mixture; adding a 6-fold to 10-fold amount of purified water and boiling with fast fire and decocting with slow fire the medicinal material mixture for 1h again, combining the filtrate, and concentrating the combined filtrate to 1/3-2/3 of the original amount to obtain an aqueous extract concentrate; 3) adding ethanol to the aqueous extract concentrate until the ethanol concentration reaches 60-80%, and placing the mixed solution in a refrigerator at 4°C for 24 h; mixing evenly and centrifugating the mixed solution, taking the supernatant and concentrating to 1/3-2/3 of the original amount, drying the concentrate under reduced pressure and crushing the dried product to obtain dry paste powder; 4) turning on a high-speed stirring granulator, setting parameters, adding the dry paste powder and a filling agent to a mixing tank, and turning on an agitator blade for dry mixing; adding a binding agent and a wetting agent evenly in a wet mixing process, and turning on a cutter knife; upon completion of granulation, discharging the granules and drying the granules at 60°C for 10-40 min; wherein the filling agent is one or more of sucrose, starch, dextrin, lactose, mannitol and sodium alginate; the filling agent is 30 wt%-60 wt%, and the binding agent is 0 wt%-5 wt%; and 5) packaging the granules. 2. The method for preparing brain-tonifying granules of claim 1, wherein the wetting agent is 1 wt%-10 wt%.2. The method for preparing brain-tonifying granules of claim 1, wherein the wetting agent is 1 wt%-10 wt%. 3. The method for preparing brain-tonifying granules of claim 2, wherein the wetting agent is 80%-95% ethanol or water.3. The method for preparing brain-tonifying granules of claim 2, wherein the wetting agent is 80%-95% ethanol or water. 4. The method for preparing brain-tonifying granules of claim 1, wherein the binding agent is one of povidone, polyethylene glycol and hydroxy propyl cellulose.4. The method for preparing brain-tonifying granules of claim 1, wherein the binding agent is one of povidone, polyethylene glycol and hydroxy propyl cellulose. 5. The method for preparing brain-tonifying granules of claim 1, wherein the parameters of the high-speed stirring granulator in step 4) are as follows: a dry mixing time is 3-5 min, a wet mixing time is 1-10 min, a granulation time is 1-4 min, a dry mixing stirring speed is 400-600 rpm, a wet mixing stirring speed is 400-600 rpm, a granulation stirring speed is 1,000-1,500 rpm, and a cutting speed is 2,000-3,000 rpm.5. The method for preparing brain-tonifying granules of claim 1, wherein the parameters of the high-speed stirring granulator in step 4) are as follows: a dry mixing time is 3-5 min, a wet mixing time is 1-10 min, a granulation time is 1-4 min, a dry mixing stirring speed is 400-600 rpm, a wet mixing stirring speed is 400-600 rpm, a granulation stirring speed is 1,000-1,500 rpm, and a cutting speed is 2,000- 3,000rpm. 6. The method for preparing brain-tonifying granules of claim 1, wherein amounts of the raw materials in step 1) are specifically as follows: 30 parts of processed Rhizoma polygonati, 30 parts of processed Rhizoma polygonati odorati, 9 parts of Semen cassiae and 3 parts of Rhizoma chuanxiong. 116. The method for preparing brain-tonifying granules of claim 1, wherein amounts of the raw materials in step 1) are specifically as follows: 30 parts of processed Rhizoma polygonati, 30 parts of processed Rhizoma polygonati odorati, 9 parts of Semen cassiae and 3 parts of Rhizoma chuanxiong. 11 BL-5573BL-5573 7. Brain-tonifying granules, prepared by the method of any of claims 1-6, LU503014 comprising an aqueous extract of plants and pharmaceutic auxiliary materials, wherein the aqueous extract of plants comprises the following parts by weight of components: 25-35 parts of processed Rhizoma polygonati, 25-30 parts of processed Rhizoma polygonati odorati, 5-15 parts of Semen cassiae and 1-5 parts of Rhizoma chuanxiong, the pharmaceutic auxiliary materials comprise a filling agent, a wetting agent and a binding agent.7. Brain-tonifying granules, prepared by the method of any of claims 1-6, LU503014 comprising an aqueous extract of plants and pharmaceutical auxiliary materials, wherein the aqueous extract of plants comprises the following parts by weight of components: 25-35 parts of processed Rhizoma polygonati, 25-30 parts of processed Rhizoma polygonati odorati, 5-15 parts of Semen cassiae and 1-5 parts of Rhizoma chuanxiong, the pharmaceutical auxiliary materials comprised a filling agent, a wetting agent and a binding agent. 8. The brain-tonifying granules of claim 7, wherein the aqueous extract of plants comprises the following parts by weight of components: 30 parts of processed Rhizoma polygonati, 30 parts of processed Rhizoma polygonati odorati, 9 parts of Semen cassiae and 3 parts of Rhizoma chuanxiong. 128. The brain-tonifying granules of claim 7, wherein the aqueous extract of plants comprises the following parts by weight of components: 30 parts of processed Rhizoma polygonati, 30 parts of processed Rhizoma polygonati odorati, 9 parts of Semen cassiae and 3 parts of Rhizoma chuanxiong. 12 BL-5573 LU503014 ANSPRÜCHEBL-5573 LU503014 ANSPRÜCHE 1. Verfahren zur Herstellung von gehirnstärkenden Kôrnchen, umfassend die folgenden Schritte: 1) Wiegen von 25-35 Teilen behandelter Rhizoma polygonati, 25-30 Teilen behandelter Rhizoma polygonati odorati, 5-15 Teilen von Semen cassiae und 1-5 Teilen von Rhizoma chuanxiong und Mischen und Zerkleinern solcher Rohstoffe, um eine Arzneistoffmischung zu gewinnen; 2) Eintauchen der in Schritt 1) hergestellten Arzneistoffmischung in eine 6- fache bis 10-fache Menge (bezogen auf eine Masse der Arzneistoffmischung) von gereinigtem Wasser für 1 h, nacheinander bei schnellem Feuer erfolgendes Kochen und bei langsamem Feuer erfolgendes Abkochen der Arzneistoffmischung für 1 h und Filtrieren der Arzneistoffmischung; Zusetzen einer 6-fachen bis 10-fachen Menge von gereinigtem Wasser und wieder bei schnellem Feuer erfolgendes Kochen und bei langsamem Feuer erfolgendes Abkochen der Arzneistoffmischung für 1 h, Vereinigen des Filtrats und Einengen des vereinigten Filtrats auf 1/3-2/3 der ursprünglichen Menge, um ein wässriges Extraktkonzentrat zu gewinnen; 3) Zusetzen von Ethanol zu dem wässrigen Extraktkonzentrat, bis die Ethanolkonzentration 60-80 % erreicht, und Stellen der Mischlôsung in einen Kühlschrank bei 4 °C für 24 h; gleichmäfiges Mischen und Zentrifugieren der Mischlésung, Nehmen des Uberstands und Einengen auf 1/3-2/3 der ursprünglichen Menge, Trocknen des Konzentrats unter reduziertem Druck und Zerkleinern des getrockneten Produkts, um ein trockenes Pastenpulver zu gewinnen; 4) Einschalten eines mit hoher Geschwindigkeit rührenden Granulators, Einstellen von Parametern, Zusetzen des trockenen Pastenpulvers und eines Füllmittels in einen Mischbehäâlter und Einschalten eines Rührflügels zum Trockenmischen; gleichmäBiges Zusetzen eines Bindemittels und eines Netzmittels in einem Nassmischverfahren und1. Verfahren zur Herstellung von gehirnstärkenden Kôrnchen, umfassend die folgenden Schritte: 1) Wiegen von 25-35 Teilen behandelter Rhizoma polygonati, 25-30 Teilen behandelter Rhizoma polygonati odorati, 5-15 Teilen von Semen cassiae und 1-5 Teilen von Rhiz oma chuanxiong und Mischen und Zerkleinern solcher Rohstoffe, um eine Arzneistoffmischung zu gewinnen; 2) Eintauchen der in Schritt 1) hergestellten Arzneistoffmischung in eine 6- fache bis 10-fache Menge (bezogen auf eine Masse der Arzneistoffmischung) von gereinigtem Wasser für 1 h, nacheinander bei schnellem Feuer erfolgendes Kochen und bei langsamem Feuer erfolgendes Ab kochen der Arzneistoffmischung für 1 hour and Filtrieren der Arzneistoffmischung; Zusetzen einer 6-fachen bis 10-fachen Menge von gereinigtem Wasser und wieder bei schnellem Feuer erfolgendes Kochen und bei langsamem Feuer erfolgendes Abkochen der Arzneistoffmischung für 1 h, Vereinigen des Filtrats und Einengen des vereinigten Filtrats auf 1/3-2/3 de r ursprünglichen Menge, um ein wässriges Extraktkonzentrat zu gewinnen; 3) Zusetzen von Ethanol zu dem wässrigen Extraktkonzentrat, bis die Ethanolkonzentration 60-80 % erreicht, und Stellen der Mischlôsung in einen Kühlschrank bei 4 °C für 24 h; gleichmäfiges Mischen und Zentrifugieren der Mischlésung, Nehmen des Uberstands und Einengen auf 1/3-2/3 der ursprünglichen Menge, Trocknen des Konzentrats unter reduziertem Druck und Zerkleinern des getrockneten Produkts, um ein trockenes Pastenpulver zu gewinnen; 4) Einschalten eines mit hoher Geschwindigkeit rührenden Granulators, Einstellen von Parametern, Zusetzen des trockenen Pastenpulvers und eines Füllmittels in einen Mischbehäâlter und Einschalten eines Rührflügels zum Trockenmischen; gleichmäBiges Zusetzen eines Bindemittels und eines Netzmittels in einem Nassmischverfahren und BL-5573 LU503014 Einschalten eines Schneidmessers; nach Vollendung der Granulation Austragen der Kôrnchen und Trocknen der Kôrnchen bei 60 °C für 10— 40 min; wobei das Füllmittel eines oder mehrere von Saccharose, Starke, Dextrin, Lactose, Mannit und Natriumalginat ist; wobei das Füllmittel 30BL-5573 LU503014 Einschalten eines Schneidmessers; nach Vollendung der Granulation Austragen der Kôrnchen und Trocknen der Kôrnchen bei 60 °C for 10— 40 min; wobei das Füllmittel eines oder mehrere von Sucrose, Starke, Dextrin, Lactose, Mannit und Natriumalginat ist; wobei das Füllmittel 30 Gew.-% bis 60 Gew.-% ausmacht und das Bindemittel 0 Gew.-% bis 5Gew.-% bis 60 Gew.-% ausmacht und das Bindemittel 0 Gew.-% bis 5 Gew.-% ausmacht; und 5) Verpacken der Kôrnchen.Gew.-% ausmacht; and 5) Verpacken der Kôrnchen. 2. Verfahren zur Herstellung von gehirnstärkenden Kôrnchen nach Anspruch 1, wobei das Netzmittel 1 Gew.-% bis 10 Gew.-% ausmacht.2. Verfahren zur Herstellung von gehirnstärkenden Kôrnchen nach Anspruch 1, wobei das Netzmittel 1 Gew.-% bis 10 Gew.-% ausmacht. 3. Verfahren zur Herstellung von gehirnstärkenden Kôrnchen nach Anspruch 2, wobei das Netzmittel 80%iges bis 95%iges Ethanol oder Wasser ist. 4 Verfahren zur Herstellung von gehirnstärkenden Kérnchen nach Anspruch 1, wobei das Bindemittel eines von Povidon, Polyethylenglykol und Hydroxypropylcellulose ist.3. Verfahren zur Herstellung von gehirnstärkenden Kôrnchen nach Anspruch 2, wobei das Netzmittel 80%iges bis 95%iges Ethanol oder Wasser ist. 4 Verfahren zur Herstellung von gehirnstärkenden Kérnchen nach Anspruch 1, wobei das Bindemittel eines von Povidon, Polyethylenglykol und Hydroxypropylcellulose ist. 5. Verfahren zur Herstellung von gehirnstärkenden Kôrnchen nach Anspruch 1, wobei die Parameter des mit hoher Geschwindigkeit rührenden Granulators in Schritt 4) wie folgt sind: eine Trockenmischzeit beträgt 3-5 min, eine Nassmischzeit beträgt 1-10 min, eine Granulationszeit beträgt 1-4 min, eine Trockenmisch-Rührgeschwindigkeit beträgt 400-600 U/min, eine Nassmisch-Rührgeschwindigkeit beträgt 400-600 U/min, eine Granulationsrührgeschwindigkeit beträgt 1.000-1.500 U/min und eine Schneidgeschwindigkeit beträgt 2.000-3.000 U/min.5. Verfahren zur Herstellung von gehirnstärkenden Kôrnchen nach Anspruch 1, wobei die Parameter des mit hoher Geschwindigkeit rührenden Granulators in Schritt 4) wie folgt sind: eine Trockenmischzeit beträgt 3-5 min, eine Nassmischzeit beträgt 1-10 min, eine Granulationszeit beträgt 1- 4 min, eine Trockenmisch-Rührgeschwindigkeit beträgt 400-600 U/min, eine Nassmisch-Rührgeschwindigkeit beträgt 400-600 U/min, eine Granulationsrührgeschwindigkeit beträgt 1.000-1.500 U/min und eine Schneidgeschwindigkeit betr ägt 2,000-3,000 U/min. 6. Verfahren zur Herstellung von gehirnstarkenden Kérnchen nach Anspruch 1, wobei die Mengen der Rohstoffe in Schritt 1) spezifisch wie folgt sind: 30 Teile behandelter Rhizoma polygonati, 30 Teile behandelter Rhizoma polygonati odorati, 9 Teile von Semen cassiae und 3 Teile von Rhizoma6. Verfahren zur Herstellung von gehirnstarkenden Kérnchen nach Anspruch 1, wobei die Mengen der Rohstoffe in Schritt 1) spezifisch wie folgt sind: 30 Teile behandelter Rhizoma polygonati, 30 Teile behandelter Rhizoma polygonati odorati, 9 Teile von Semen cassiae und 3 Teile von Rhizoma BL-5573 LU503014 chuanxiong.BL-5573 LU503014 chuanxiong. 7. Gehirnstarkende Koérnchen, hergestellt durch das Verfahren nach irgendeinem der Ansprüche 1-6, umfassend einen wässrigen Pflanzenextrakt und pharmazeutische Hilfsstoffe; wobei der wässrige Pflanzenextrakt die folgenden Gewichtsteile von Bestandteilen umfasst: 25— 35 Teile behandelter Rhizoma polygonati, 25-30 Teile behandelter Rhizoma polygonati odorati, 5-15 Teile von Semen cassiae und 1-5 Teile von Rhizoma chuanxiong; wobei die pharmazeutischen Hilfsstoffe ein Füllmittel, ein Netzmittel und ein Bindemittel umfassen.7. Gehirnstarkende Koérnchen, hergestellt durch das Verfahren nach irgendeinem der Ansprüche 1-6, umfassend einen wässrigen Pflanzenextrakt und pharmazeutische Hilfsstoffe; wobei der wässrige Pflanzenextrakt die folgenden Gewichtsteile von Bestandteilen umfasst: 25— 35 Teile behandelter Rhizoma polygonati, 25-30 Teile behandelter Rhizoma polygonati odorati, 5-15 Teile von Semen cassiae und 1-5 Teile von Rhizoma chuanxiong; wobei die pharmazeutischen Hilfsstoffe ein Füllmittel, ein Netzmittel und ein Bindemittel umfassen. 8. Gehirnstärkende Kôrnchen nach Anspruch 7, wobei der wässrige Pflanzenextrakt die folgenden Gewichtsteile von Bestandteilen umfasst: 30 Teile behandelter Rhizoma polygonati, 30 Teile behandelter Rhizoma polygonati odorati, 9 Teile von Semen cassiae und 3 Teile von Rhizoma chuanxiong.8. Gehirnstärkende Kôrnchen nach Anspruch 7, wobei der wässrige Pflanzenextrakt die folgenden Gewichtsteile von Bestandteilen umfasst: 30 Teile behandelter Rhizoma polygonati, 30 Teile behandelter Rhizoma polygonati odorati, 9 Teile von Semen cassiae und 3 Teile von Rhizoma chu anxious.
LU503014A 2022-04-22 2022-11-08 BRAIN-TONIFYING GRANULES AND PREPARATION METHOD THEREOF LU503014B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210431160.6A CN114569671A (en) 2022-04-22 2022-04-22 Brain-nourishing granule and preparation method thereof

Publications (1)

Publication Number Publication Date
LU503014B1 true LU503014B1 (en) 2023-05-16

Family

ID=81785877

Family Applications (1)

Application Number Title Priority Date Filing Date
LU503014A LU503014B1 (en) 2022-04-22 2022-11-08 BRAIN-TONIFYING GRANULES AND PREPARATION METHOD THEREOF

Country Status (2)

Country Link
CN (1) CN114569671A (en)
LU (1) LU503014B1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105194318A (en) * 2015-10-23 2015-12-30 韩俊峰 Compound traditional Chinese medicine brain-strengthening decoction and preparation method thereof
CN107308323B (en) * 2017-06-26 2020-08-18 杭州寿而健健康产品有限公司 Brain-nourishing oral liquid and its preparation process
CN110882323B (en) * 2019-06-17 2022-04-29 广西中医药大学附属瑞康医院 Granules for enhancing constitution of sub-healthy people and preparation method thereof

Also Published As

Publication number Publication date
CN114569671A (en) 2022-06-03

Similar Documents

Publication Publication Date Title
CN102284020A (en) Composite with actions of relieving alcoholism and protecting liver and preparation method and applications thereof
CN112972547A (en) Traditional Chinese medicine composition for treating qi-blood deficiency syndrome and preparation method and application thereof
CN105456622A (en) Traditional Chinese medicinal composition for treating impaired glucose regulation, preparation, and preparation method thereof
CN102614281B (en) Chinese medicinal composition for improving anoxia endurance and preparation method and application thereof
CA2702711A1 (en) Liquid preparation containing herb and/or animal-origin extract
CN107335401B (en) Method for removing pesticide residues in traditional Chinese medicine ointment formula by using inorganic adsorbent
CN108014150A (en) Application of the natural drug composition in anti anoxia and radiation-resistant medicine or food is prepared
CN108785412B (en) Composition with function of improving sleep and preparation method thereof
CN107308323B (en) Brain-nourishing oral liquid and its preparation process
CN104116963A (en) Radix fici simplicissimae compound preparation for resisting oxidation and delaying senescence and preparation method of radix fici simplicissimae compound preparation
LU503014B1 (en) BRAIN-TONIFYING GRANULES AND PREPARATION METHOD THEREOF
CN104147394A (en) Dendrobium candidum compound preparation and preparation method thereof
CN101024066A (en) Jinsangliyan preparation and preparing method
CN1969963A (en) Method for extracting medicament effective component for treating hepatitis and medicinal composition thereof
CN1872232B (en) Composition of medication for curing cerebrovascular disease, and preparation method
CN111714539B (en) Liver-protecting composition and preparation method and application thereof
CN104338017B (en) Pharmaceutical composition with sleep improvement effect, preparation method and application thereof
CN113633714A (en) Preparation method of golden fruit beverage
CN107823380B (en) Preparation method of compound kidney-tonifying traditional Chinese medicine composition
CN111419946A (en) Medicine for treating infertility and preparation method thereof
CN110251624B (en) Preparation method of acne eliminating gel
CN110101753A (en) A kind of preparation method and purposes of compound ganoderma extractive composition
CN116889598B (en) Preparation method of Jiangzhiping oral liquid and its products and use
CN104000180A (en) Ginseng compound assisting in blood sugar level regulation and preparing method and application thereof
CN107753551B (en) Composition with function of reducing blood pressure and preparation method thereof